# Savolitinib Plus Cetuximab and FOLFOX Chemotherapy for RAS/BRAF Wild-type Metastatic Colorectal Cancer

> **NCT07683403** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Fudan University** · enrollment: 138 (estimated)

## Conditions studied

- Colorectal Cancer (CRC)

## Interventions

- **DRUG:** Savolitinib plus cetuximab and FOLFOX chemotherapy
- **DRUG:** Cetuximab and FOLFOX chemotherapy

## Key facts

- **NCT ID:** NCT07683403
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-30
- **Primary completion:** 2028-06-30
- **Final completion:** 2029-06-30
- **Target enrollment:** 138 (ESTIMATED)
- **Last updated:** 2026-07-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07683403

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07683403, "Savolitinib Plus Cetuximab and FOLFOX Chemotherapy for RAS/BRAF Wild-type Metastatic Colorectal Cancer". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07683403. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*